TEAR Stock UPDATES Tearlab Corp (TEAR) 4.43 08/02/2014 16:06

New Post Public Reply Private Reply Replies (0) Message Board

Aug 2, 2014 at 5:06 PM

Tearlab Corp (TEAR) 4.43 $TEAR

WEALTHMAKERS.COM Issues Bearish Research Reports on SLAB, TAP, TEAR, UAN, VICL, VSAT
M2 - Wed Jul 30, 9:44AM CDT
WEALTHMAKERS.COM / www.wealthmakers.com , a Wall Street research and trading firm providing unbiased statistical stock market predictions to empower investors, securities professionals and public company employees to make precise, predictive and profitable trading decisions, has issued new research reports today on the following stocks: Silicon Laboratories Inc (NASDAQ:SLAB), Molson Coors Brewing Co (NYSE:TAP), Tearlab Corp (NASDAQ:TEAR), CVR Partners LP (NYSE:UAN), Vical Inc (NASDAQ:VICL), VIASAT, INC. (NASDAQ:VSAT)

TearLab Corporation to Release Q2 2014 Financial Results on August 7, 2014
GlobeNewswire - Wed Jul 16, 4:30PM CDT
TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) expects to announce its Q2 2014 financial results after market closes on Thursday, August 7, 2014. TearLab is pleased to invite all willing participants in a conference call during which time financial results will be discussed. That call will be held at 4:30pm Eastern at 877-303-1593.

Manoj Venkiteshwar Joins TearLab as VP of Medical Affairs
GlobeNewswire - Mon Jul 14, 3:15PM CDT
TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) ("TearLab" or the "Company"

today announced the appointment of Manoj S. Venkiteshwar, PhD. to its senior management team in the newly created position of Vice President of Medical Affairs.

Nasdaq stocks posting largest percentage increases
AP - Thu Jul 03, 12:17PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:

Financial Guidance, Appointments, Board Elections, and Technical Updates - Analyst Notes on Amedisys, Dyax, TearLab, Celladon and Alphatec
PR Newswire - Wed Jul 02, 5:00AM CDT
Today, Analysts Review released its analysts' notes regarding Amedisys Inc. (NASDAQ: AMED), Dyax Corp. (NASDAQ: DYAX), TearLab Corp. (NASDAQ: TEAR), Celladon Corp. (NASDAQ: CLDN) and Alphatec Holdings Inc. (NASDAQ: ATEC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4350-100free.

TearLab Announces Election of Directors
GlobeNewswire - Fri Jun 13, 3:02PM CDT
TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) ("TearLab" or the "Company"

announced that all of the nominees listed in the management information circular for the annual meeting of shareholders held on Wednesday, June 11, 2014 were elected as directors of the Company.

TearLab to Participate in the 11th Annual Craig-Hallum Institutional Investor Conference
GlobeNewswire - Wed May 21, 4:01PM CDT
TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) ("TearLab" or the "Company"

announced today that its Chief Executive Officer, Elias Vamvakas, will participate in the 11th Annual Craig-Hallum Institutional Investor Conference on Wednesday, May 28, 2014. The conference will be held at the Minneapolis Marriott City Center Hotel.

TearLab Closes Acquisition of AOA's OcuHub Technology Platform
GlobeNewswire - Fri Mar 14, 11:30AM CDT
TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) ("TearLab" or the "Company"

today announced the closing of the acquisition of the assets of the OcuHub business unit from AOAExcel, Inc., the for-profit subsidiary of the American Optometric Association ("AOA"

.

TearLab Corporation Reports 2013 Financial Results
GlobeNewswire - Thu Mar 13, 3:02PM CDT
TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) ("TearLab" or the "Company"

today reported its consolidated financial results for the quarter and the year ended December 31, 2013. All dollar amounts are expressed in U.S. currency and results are reported in accordance with United States generally accepted accounting principles.

5 Hated Earnings Stocks You Should Love
at The Street - Tue Mar 11, 11:27AM CDT
These heavily shorted stocks could get squeezed much higher if they report positive earnings this week.

TearLab to Participate in March Investor Conferences
GlobeNewswire - Tue Mar 04, 8:00AM CST
TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) ("TearLab" or the "Company"

announced today that the Company will participate in three investor conferences in March.

TearLab Corporation to Release Q4 and Full Year 2013 Financial Results on March 13, 2014
GlobeNewswire - Mon Mar 03, 3:30PM CST
TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) expects to announce its Q4 2013 and full year 2013 financial results after market closes on Thursday, March 13, 2014. TearLab is pleased to invite all willing participants in a conference call during which time financial results will be discussed. This call will be held at 4:30pm Eastern at 877-303-1593.

3 Stocks Under $10 Moving Higher
at The Street - Fri Feb 28, 5:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

TearLab to Acquire AOA's OcuHub Technology Platform
GlobeNewswire - Tue Feb 18, 7:02AM CST
TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) ("TearLab" or the "Company"

today announced it has signed a non-binding term sheet to purchase the assets of the OcuHub business unit from AOAExcel, Inc., the for-profit subsidiary of the American Optometric Association ("AOA"

.

5 Stocks Ready to Explode Higher
at The Street - Wed Feb 12, 1:13PM CST
These stocks could be sett9ing up for explosive moves higher soon.

TearLab Announces Preliminary Fourth Quarter 2013 Revenue and Issues 2014 Revenue Guidance
GlobeNewswire - Mon Feb 03, 7:00AM CST
TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) ("TearLab" or the "Company"

today announced total revenue for the fourth quarter of 2013 is expected to be approximately $4.5 million, bringing expected full year 2013 revenues to approximately $14.7 million. These figures are preliminary and unaudited and final revenues may differ. The Company currently expects to report final 2013 financial results on March 13, 2014.

TearLab (TEAR) in Focus: Stock Tumbles 7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jan 29, 7:39AM CST
TearLab ompany’s shares fell by over 7% yesterday. This recent price action is discouraging, so make sure to keep a close watch on this firm in the near future, and especially on earnings estimates following the recent slump.

TearLab Reports on Launch of a New 1,000 Patient Multi-Center DED Prevalence Study in the UK
GlobeNewswire - Tue Dec 17, 7:00AM CST
In collaboration with the United Kingdom's National Health Service (NHS), four ophthalmologists are beginning a large 1,000 patient multi-center study to assess the overall prevalence of Dry Eye Disease ("DED"

.

TearLab to Participate in Craig-Hallum's 4th Annual Alpha Select Conference
GlobeNewswire - Thu Sep 19, 8:20AM CDT
TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) ("TearLab" or the "Company"

announced today that its Chief Executive Officer, Elias Vamvakas, will present an update on the Company's business at the 4th Annual Craig-Hallum Alpha Select Conference on Thursday, September 26, 2013 at 8:35 a.m. Eastern Time in New York City.

Dividends, Diverse Product Pipelines, Acquisitions, Financial Results - Research Report on Quest Diagnostics, PerkinElmer, Waters, Alere, and TearLab
PR Newswire - Tue Sep 03, 7:00AM CDT
Editor Note: For more information about this release, please scroll to bottom.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

UWM Faces Class Action Deadline: Key Insights for Investors

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

GORGIE Unleashes Berry Burst: Target's New Drink Star

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

MRI Surveillance Gains Ground in Lung Cancer Care

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

First-Time Homeowners: Unseen Pitfalls of Insurance

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Ris-Rez May Set New Standard in Relapsed SCLC

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Trial Disappointment: No Significant Gains in NSCLC

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

PwC US and India Unite for Global Consultancy Powerhouse

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Surfing Dogs Ride Waves, Support Orphan Pets

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...